Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib
Go back to Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib| COGENT (NASDAQ: COGT) | Delayed: 31.43 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $31.43 | 52 Week High | $5.57 | |||
| Open | $31.43 | 52 Week Low | $2.90 | |||
| Day High | $31.43 | P/E | 142.86 | |||
| Day Low | $31.43 | EPS | $0.22 | |||
| Volume | 10 | |||||
